Navigation Links
Mayo Clinic: Preclinical tests may lead to new approach to treat CNS lymphoma
Date:8/12/2013

JACKSONVILLE, Fla. -- A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic -- in Florida, Minnesota and Arizona -- follows successful testing of the drug, pomalidomide, in mouse models of CNS lymphoma. Details of the preclinical testing are available in the science journal PLOS ONE.

Approximately 5,000 patients are diagnosed with the disease every year in the United States.

"We believe pomalidomide could be beneficial in patients with this cancer because it does two things that most anti-cancer drugs do not do," says Han Tun, M.D., an oncologist at Mayo Clinic in Florida. "The drug has excellent brain penetration, which is a requirement in treatment of brain tumors. The other interesting thing is that it is not only active directly against lymphoma cells but also alters the tumor microenvironment."

Dr. Tun is the senior investigator of the PLOS ONE study and the principal investigator for the clinical trial, which is accruing patients.

"Our preclinical study suggests pomalidomide is very promising. Treatment with pomalidomide in mouse models for CNS lymphoma significantly improved the survival and suppressed the tumor growth," he says. "The phase I clinical trial was developed based on these preclinical results."

Pomalidomide belongs to a class of drugs called immunomodulatory agents. Thalidomide was the first drug in this class and was approved in 2006 for treatment of multiple myeloma, a bone marrow cancer. Pomalidomide was approved for use in multiple myeloma in February.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
2. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
3. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
4. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
5. Mayo Clinic: Common blood pressure drug linked to severe GI problems
6. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
7. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
8. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
9. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
10. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
11. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... thousands of defective respirators, according to court documents and SEC filings. A ... and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
Breaking Medicine Technology: